Medgate Today

JBCPL EMERGES AS THE FASTEST GROWING PHARMA COMPANY

-

Ranked 25th with an impressive growth rate of 29% in Indian Pharma Companies in FY 2021-22 5 brands of JBCPL are ranked in the top 300 pharmaceut­ical brands of the Indian Pharmaceut­ical Market 4 of JBCPL'S brands (including Azmarda) rank in the top 100 in the Cardiac Therapy

Amid the ongoing COVID pandemic and the crisis created by it, JB Chemicals & Pharmaceut­icals Ltd., has emerged as the fastest growing pharmaceut­icals company amongst the top 25 companies in the Indian Pharmaceut­ical Market during the Financial Year 2021-22 registerin­g an impressive growth rate of 29% outperform­ing the market rate of 18% as per the moving annual turnover (MAT) basis in March 2022. More so, 5 brands of JBCPL are ranked in the top 300 pharmaceut­ical brands of the Indian Pharmaceut­ical Market. Elated on the spectacula­r growth of JBCPL, Nikhil Chopra, CEO & Whole Time Director, JBCPL said, “We have made a remarkable growth during the financial year 202122. Though currently, we are ranked 25 in the Indian Pharmaceut­ical Market, we target to have the company rank in the top 20 pharmaceut­ical firms. We have outperform­ed in the cardiac segment with 3 of its brands marking their presence in the top 300 brands of Indian Pharmaceut­ical Market.”

The company has also gained ranks from 32 as of moving annual turnover (MAT) March 2020 to rank 25 in March 2022 and with the newly acquired brands from Sanzyme and the latest addition of Azmarda from April 2022, JBCPL is likely to gain even more ranks in the coming years.

JB sales as per IQVIA MAT 22 was at INR 1490.7 crores as compared to INR 1157.4 crores a year back recording growth of 28.8 % for FY 22. JB was the fastest growing pharmaceut­ical company in FY 2021-22. The second fastest growing pharma company among the top 25 as per IQVIA is Alkem which recorded sales as per IQVIA MAT 22 at INR 7244 crores as compared to INR 5676 crores growing at 27.6 % for the financial year. The third fastest growing pharma company among the top 25 as per IQVIA is ARISTO which recorded sales as per IQVIA MAT 22 at INR 5459 crores as compared to INR 4352 crores growing at 25.4 % for the financial year.

“We are delighted to be the fastest-growing company in the FY 2021-22. This has been possible because of the continued focus on its core therapy areas. Further, this growth has been achieved with an insignific­ant contributi­on from the COVID portfolio, which reflects the underlying growth momentum of our core business. We remain confident that we will continue to outperform the Indian Pharmaceut­ical Market (IPM), and drive growth by focusing on our core therapy areas. Last year, we focused on building capabiliti­es and focused on building a culture that will drive growth. We reached out to every employee to build a cohesive culture,” said, Dilip Singh Rathore, President, Domestic Business, JBCPL.

With the strong placement in the cardiac segment, JBCPL has moved up three ranks in the therapy from 16 as moving annual turnover (MAT) from March 2020 to 13 by March 2022, while growing with a CAGR of 22.73%, beating the segment growth rate which is 12% over the same period. 4 of JB'S brands (including Azmarda) rank in Top 100 in the Therapy, all growing at a very healthy pace.

 ?? ?? DILIP SINGH RATHORE
DILIP SINGH RATHORE
 ?? ??
 ?? ??

Newspapers in English

Newspapers from India